Please login to the form below

Not currently logged in
Email:
Password:

Label update for simvastatin

The US Food and Drug Administration has announced changes to the prescribing information for cholesterol medication, simvastatin, after the drug was linked to an elevated risk of muscle injury or myopathy

The US Food and Drug Administration (FDA) has announced changes to the prescribing information for cholesterol medication, simvastatin, after the drug was linked to an elevated risk of muscle injury or myopathy.

The updates will be made to the label of products containing the highest approved dose of simvastatin (80mg), including Zocor, marketed by Merck. Outside the US and Canada, Merck is known as MSD.

The FDA recommends simvastatin 80mg only be used in patients who have been taking the dose for at least year without muscle-related problems. The drug should not be prescribed to new patients. Further contraindications have also been added to the drug's information.

In 2010, about 2.1 million patients in the US were prescribed a product containing simvastatin 80mg.

"We encourage those who think these changes might affect them to talk to their doctor," said Dr Michael Rosenblatt, chief medical officer for Merck. "Patients should talk with their doctor before they stop taking any of their medicines. We are committed to communicating these changes to help physicians and their patients understand the updated recommendations for use of this important medicine."

9th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics